Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Combination With BRAF/MEK Inhibitors in BRAF V600 Mutant Metastatic Melanoma
NCT04903119Phase 1Recruiting
- Start
- Jun 2022
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nilotinib in melanoma (4 arms). Primary endpoint: Percentage of Patients Experiencing Dose Limiting Toxicities at 28 days. Started Jun 2022; status: recruiting.
02
Drugs
nilotinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04903119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903119.